COEP
Coeptis Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.99
−8.57%Price chart
Jun 30Jul 6Jul 9Jul 14Jul 17Jul 22Jul 27Jul 30
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.4x
Market Cap
$52.15M
MomentumView details →
1D Return
−8.57%
YTD Return
−63.37%
RSI (14)
37.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.4x
Market Cap
$52.15M
RSI (14)
37.7
MomentumView details →
1D Return
−8.57%
YTD Return
−63.37%
SummaryUpdated Mar 1, 2026
Coeptis Therapeutics, Inc. (NASDAQ:COEP) is a biopharmaceutical company founded in 2017 and headquartered in Wexford, Pennsylvania. The company went public in December 2020 and focuses on developing innovative cell therapy platforms and pharmaceutical products for cancer treatment. Coeptis operates in the highly specialized field of immuno-oncology, developing treatments that harness the body's immune system to fight cancer. The company is currently in the clinical development stage with no approved products generating significant revenue, making it a typical early-stage biotech investment with high risk and potential reward characteristics.
Similar companies
Latest newsMore news →
Z Squared Inc. entered into a sales agreement with Roth Capital Partners, LLC to offer and sell up to $300 million of its common stock in an at-the-market offering.60d agoZ Squared Inc. signed a $50 million committed equity forward purchase agreement on May 29, 2026, for the sale of its common stock in reliance on Section 4(a)(2) of the Securities Act and Regulation D.93d ago